Jade BiosciencesJBIO
Recorded

Jade Biosciences Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Phoebe TanSenior Biotechnology Equity Research Associate

Hi, everyone. This is Phoebe Tan, and I work with Akash Tewari at Jefferies. Today, I have the pleasure of hosting Jade Biosciences, and I will pass it over to Tom, the CEO, and Andrew, the President of R&D, for intro remarks.

Tom FrohlichCEO

Great. Thanks so much for hosting us, Phoebe and the whole Jefferies team. It is great to be here in London. Just a quick overview into Jade. We are a company focused on developing best-in-class therapies across a number of different autoimmune diseases. Our lead program is JADE101. It is an anti-APRIL therapy targeting IgA nephropathy at the outset. Really exciting program designed for ultra-high affinity binding to APRIL and a half-life extension to have long duration of action. We released some data in June this year on a phase I trial in healthy volunteers, which gave us conviction on a best-in-class approach to the disease. We showed really deep and robust reductions of IgA in the disease, more than has seen with any other first-generation agent.

Tom FrohlichCEO

And those deep, robust reductions in IgA was actually sustained for a 12-week period, giving us confidence we will have extended dosing to provide really optimal dosing for patients and minimize treatment burden for them, aiming to have a acute 12-week dose. We started a phase II around the same time, and so we are moving rapidly towards a phase II readout. We have guided that we are going to provide data in the second quarter of next year, but we are not waiting for that data to initiate a phase III. We have actually recently updated our guidance to say we will initiate the phase III trial in IgA nephropathy this quarter. So moving extremely quickly towards registrational data and marketing approval there potentially. So that is a very exciting program. Our second program is called JADE201. It is a BAFF receptor targeting antibody. It is afucosylated, has a very exciting mechanism of action for B-cell depletion.

Tom FrohlichCEO

We are aiming to get TCE-like efficacy in terms of B-cell depletion, but do it without some of the cytokine release syndrome effects that you do see with TCEs. This program is really following in the footsteps of ianalumab, which is a program that is at Novartis, currently in a number of different phase IIIs, had positive data in Sjögren's last year and is heading towards approval. JADE201 actually improves upon that profile by having a longer duration of action, so potentially providing benefits of better coverage of the target and better dosing for patients as well. Currently in a rheumatoid arthritis trial with that agent, aiming to read out data in 2027. Our third program, JADE301, and then we will pass it back to you for questions, is newly disclosed. It is targeting interferon beta.

Tom FrohlichCEO

We'll initially develop that in a disease called dermatomyositis, which is a severe disease that causes neuromuscular and skin complications for patients. We're about to enter a phase I study for that in healthy volunteers, aiming to have data on that in the second half of 2027. That's a really exciting opportunity where potentially we have a best-in-disease profile there for that asset. So it's three really exciting assets that we're looking to have readouts next year on.

Phoebe TanSenior Biotechnology Equity Research Associate

Perfect. Thank you for the intro. Just starting with JADE101. You'll have phase II JUNIPER data Q2 2027. So first, I guess, what magnitude and durability of proteinuria reduction do you consider a win here and very competitive versus benchmarks? And two, in terms of the market, we have sibeprenlimab, a lot of different players coming into the IgAN market. So where do you think key differentiation for JADE101 comes into play?

Tom FrohlichCEO

Yeah. Andrew, why don't you take the expectations around the JUNIPER study, and then I'll take the differentiation.

Andrew KingPresident of Research and Development

Yeah. The JUNIPER trial is a relatively small, 30-patient, open-label IgAN study. Our goal with JADE101 is to provide the full disease-modifying benefit of B-cell modulation with a Q12-week maintenance dosing interval to deliver infrequent dosing to this young, otherwise healthy IgAN patient population needing lifelong therapy potentially for decades. Because this study is relatively small in sample size, we don't want to anchor quantitatively too much on a specific reduction in proteinuria, just given the biologic variability of proteinuria in a small sample size. But it's really the totality of the data to replicate the rapid and deep IgA reductions that we observed in the healthy volunteer study, accompanied by depletion of pathogenic Gd-IgA1, and then proteinuria reductions in the ballpark of the first-generation agents, which have typically been around 50% also.

Andrew KingPresident of Research and Development

If we can do that and maintain it with a Q12-week dosing interval, we think we will have an exceptional profile that is differentiated to move forward. Based on the phase I data, we do see more rapid and deeper reductions in IgA, and we think that has the potential to translate to earlier reductions in proteinuria than the first-generation agents, and particularly the potential to deliver more patients back to within the target ranges from the KDIGO guidelines, below 0.5 grams per day and preferably below 0.3 grams per day.

Tom FrohlichCEO

Yeah, so I think you covered the main points on differentiations. We think IgAN is a very large market size. There is about 170,000 patients in the U.S. alone. 60%-75% of those are above half a gram of proteinuria a day, which really defines those patients at risk of disease progression and are eligible for this class of therapies. So we believe in the U.S. alone, it is a $20 billion plus market opportunity. The first-generation agents, sibeprenlimab, which is a selective anti-APRIL, and then Vera's atacicept have recently been approved and are off to very good launches, really showing the demand out there in the market for these novel medications. But as Andrew described, we think we can really positively differentiate from those agents, first of all by being selective on APRIL, which we think is really the pathogenic driver of the disease.

Tom FrohlichCEO

Second, on really capturing that efficacy by having an ultra-potent molecule that allows to have those really deep reductions in IgA that will translate into really robust levels of proteinuria reduction and get more patients into the target zone. Then as Andrew also pointed out, these patients are typically diagnosed fairly young, in their 20s and 30s, and their lifetime probability of having disease progression and kidney function loss is extremely high, so they need lifelong therapy. So we believe having those Q12-week dose interval really control their disease with only four injections a year will be a really big differentiator versus the competition. So we feel really confident we have got a best-in-disease molecule, which will capture a significant portion of that share.

Phoebe TanSenior Biotechnology Equity Research Associate

Great. Then in terms of how much data we will get from the readout, can you just kind of describe how much we will get, then should we expect a press release or data at a medical conference, maybe ERA?

Andrew KingPresident of Research and Development

Yeah, we have guided on initial interim analysis of that study in Q2 of next year, so ERA does make a lot of sense, typically in June. That would be a likely venue for presentation. We do like to present at medical conferences. This phase II data is really not decision-making for the phase III, as we plan to initiate that before the end of this year, but is really to be able to generate data for external disclosure, particularly for investigators of that phase III trial, to drive enthusiasm for enrollment. A medical conference is very helpful from that perspective. We initiated enrollment in May of this year, so the dataset in Q2 of next year will include those initial patients out through about nine months of treatment, and then increasing numbers of patients at earlier time points.

Andrew KingPresident of Research and Development

We haven't provided blow-by-blow updates on enrollment in that study, but we do think we'll have a very meaningful dataset in Q2 of next year.

Phoebe TanSenior Biotechnology Equity Research Associate

Perfect. Then moving on to the phase III. You've planned to initiate that this Q4, prior to reading out your phase II. Number one, what is driving the confidence here? Number two, how much time are you saving by starting it now rather than waiting for the phase II to read out? Number three, has the FDA required seeing any interim or any initial data from your phase II that kind of gave you and the FDA confidence to move forward with the phase III?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day